Intron-derived aberrant splicing of A20 transcript in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 3, 2013, Pages 427-437

  Yoon, Hyun Kyung ^a   Byun, Hee Sun ^a   Lee, Hyunji ^a   Jeon, Juhee ^a   Lee, Yoonjung ^a   Li, Yuwen ^a   Jin, Eun Heui ^a   Kim, JaeWoo ^a   Hong, Jang Hee ^a   Kim, Jin Hyun ^a   Seok, Jeong Ho ^a   Kang, Seong Wook ^a   Lee, Won Hyung ^a   Hur, Gang Min ^a  

^a Chungnam National University   (South Korea)

Author keywords

A20; Aberrant splicing variants; Nf b; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

A20 PROTEIN; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RNA SPLICING; SIGNAL TRANSDUCTION; STOP CODON; SYNOVIOCYTE;

ALTERNATIVE SPLICING; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DNA-BINDING PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 84874068033     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes292     Document Type: Article

References (37)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008;275:4448-55.
3. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011;17:3141-54.
4. Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001; 15:2321-42.
5. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995;9: 2723-35.
6. Cavalcante LO, Melo MR, Dinis VG, Castro RB, Souza BD, Longui CA. Quantitation of glucocorticoid receptor alpha and NF-kB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. Genet Mol Res 2010;9:2300-10.
7. Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. Immunol Rev 2010;233:55-61.
8. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology 2008;47:584-90.
9. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004;50:1781-7.
10. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-56.
11. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 1996;39:197-203.
12. Yamasaki S, Kawakami A, Nakashima T et al. Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001;60:678-84.
13. Boone DL, Turer EE, Lee EG et al. The ubiquitin modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-60.
14. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009; 284:8217-21.
15. Renner F, Schmitz ML. Autoregulatory feedback loops terminating the NF-kB response. Trends Biochem Sci 2009;34:128-35.
16. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009;30:383-91.
17. Wertz IE, O'Rourke KM, Zhou H et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694-9.
18. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-4.
19. Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-6.
20. Schmitz R, Hansmann ML, Bohle V et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206: 981-9.
21. Boonyasrisawat W, Eberle D, Bacci S et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 2007;56:499-505.
22. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:708-14.
23. Musone SL, Taylor KE, Lu TT et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40: 1062-4.
24. Tejasvi T, Stuart PE, Chandran V et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012;132: 593-600.
25. Hah YS, Lee YR, Jun JS et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum 2010;62: 2313-21.
26. Man JH, Li HY, Zhang PJ et al. PIAS3 induction of PRB sumoylation represses PRB transactivation by destabilizing its retention in the nucleus. Nucleic Acids Res 2006;34: 5552-66.
27. Lukas J, Gao DQ, Keshmeshian M et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61: 3212-9.
28. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003; 301:836-8.
29. Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005;7: 1-20.
30. Billmann-Born S, Till A, Arlt A et al. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's diseaseassociated NOD2 variant L1007fsinsC. J Immunol 2011; 186:4027-38.
31. Douglas AG, Wood MJ. RNA splicing: disease and therapy. Brief Funct Genomics 2011;10:151-64.
32. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
33. Plenge RM, Cotsapas C, Davies L et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-82.
34. Thomson W, Barton A, Ke X et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:1431-3.
35. Orozco G, Hinks A, Eyre S et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 2009;18: 2693-9.
36. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003;3:317-22.
37. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004;9: 2323-34.